Webinars & Presentations

Induced pluripotent stem cell colony

Webinars & Presentations

  • World Class Expert Guest Speakers & Guest Moderators
  • Most webinars are moderated by Jeanne Loring, PhD
  • Patients, Medical Professionals, Researchers, Students, & Public – EVERYONE is Welcome!
  • Thanks to the generosity of our sponsors, our webinars are FREE to our attendees. 
  • For more information about our Webinar Planning Committee, please go to the SUMMIT TEAM page.
  • Please note: Content, date, and time are subject to change.
SPECIAL EDITION Summit Sentinel FALL 2023

If you enjoy our Educational Programs, PLEASE help us continue to provide these webinars and programs like them by DONATING today!

  • This 4-part webinar series is focused on the Autologous Cell-based therapy for Parkinson’s disease as it nears FDA-approved Clinical Trials.
  • You must register for each webinar separately to attend each webinar.
  • Questions can be submitted at the time of registration.
  • Please be sure to check for “Hand-outs”, Surveys, or documents to download at the time of registration and/or when you enter the webinar.

This webinar was aired 11/09/23.
A recording of this webinar can be viewed by clicking the button below. 
Aspen Neuroscience
Autologous Cell Therapy for Parkinson’s disease:
Recent Updates from Aspen Neuroscience and an Overview of Autologous Cell Therapy
Featured Guest Speakers: 
Damien McDevitt, PhD  – President & Chief Executive Officer, Aspen Neuroscience
Ana Sousa – Senior Vice President, Regulatory Affairs & Quality
Moderator: Jeanne Loring, PhD
Panelists: Rita Ceponiene, MD, PhD; Melissa King, MBA; Jenifer Raub, President, Summit for Stem Cell Foundation

Parkinson’s Disease is a neurodegenerative disease caused by loss of dopaminergic (DA) neurons in the nigrostriatal pathway that leads to progressive loss of motor and neurological function. It is the second most common neurodegenerative movement disorder (after Alzheimer’s), affecting 1 million people in the U.S. alone. PD symptoms (impairments in movement, coordination, speech, and cognition) severely affect quality of life and patient life span. Current therapies are not curative, decrease in effectiveness over time, and can have side effects that impact patient quality of life. Since motor symptom severity correlates with the loss of DA neurons, cell replacement therapy holds great promise for restoring brain function.

ANPD001 is a novel, personalized, regenerative cell therapy. It is composed of dopaminergic neuron precursor cells (DANPCs) derived from autologous induced pluripotent stem cells (iPSCs) from the skin biopsies of PD patients. Aspen’s preclinical data shows that DANPCs transplanted into animal models differentiate into DA neurons that integrate into the brain and halt of reverse PD symptoms. This year ANPD001 received FDA IND clearance in August and Fast Track Designation in October. In 2022, Aspen established an interventional trial-ready cohort screening study, and screened and recruited people with mid-stage to moderately advanced sporadic PD, and collected skin biopsies. We are now generating iPSCs from these biopsies and manufacturing clinical-grade ANPD001. To support the first cohort, ANPD001 for three (3) patients has been manufactured.

More information about the Phase 1/2a study will be announced soon.

Damien McDevitt, PhD – President and Chief Executive Officer

A distinguished leader in the biotech and pharmaceutical industry sectors, Damien is recognized for his vision, strategic planning, and corporate leadership. With a career spanning more than 25 years, he has served in multiple board and executive leadership roles including most recently as CEO of rare diseases company Akcea Therapeutics, Inc.

Prior to joining Akcea, Damien held senior executive roles at Ionis Pharmaceuticals, Acadia Pharmaceuticals and GlaxoSmithKline Pharmaceuticals. Damien received his BA and PhD at Trinity College Dublin, Ireland, and completed a post-doctoral research fellowship at the Institute of Biosciences and Technology, Texas A&M.

Ana Sousa, MSJ – Senior Vice President, Regulatory Affairs and Quality

Ana Sousa brings a depth of expertise to her role as Senior Vice President of Regulatory Affairs for Aspen Neuroscience. With twenty years of experience in global regulatory affairs, Ana combines large company experience with the agility of a small biotech mindset. Prior to Aspen, Ana led Global Regulatory Affairs and Quality for Principia Biopharma, where she focused on bringing transformative therapies to patients with serious immune-mediated diseases by changing the way small molecules are developed. Prior to Principia she held positions of increased leadership with Immune Design, Onyx Pharmaceuticals, and Genentech-Roche.

Ana received her undergraduate degree at Pace University, Lubin School of Business, and her Master of Science in Jurisprudence (MSJ) degree with a concentration in Health Law and Intellectual Property at The Seton Hall University School of Law.

Claire Henchcliffe, MD, PhD


This webinar was aired 12/07/23.
A recording of this webinar can be viewed by clicking the button below. 

Update: Cell Based Therapies Around the World
DATE: Thursday. December 7th, 2023
TIME: 5:00-7:00pm PST
FEATURED SPEAKER: Claire Henchcliffe, M.D., D.Phil.

In the realm of Parkinson’s disease research, there is a notable resurgence of interest in experimental cell-based approaches to therapy, particularly in the context of transplant procedures. Recent strides in stem cell technology allow almost unlimited and highly controlled production of dopamine neurons and their progenitors. Now, multiple research groups are revisiting the potential of transplanting cells into the putamen of patients with Parkinson’s disease, aiming to replace damaged dopamine neuronal inputs with healthy stem cell-derived ones. The hope is that such experimental therapies, whether derived from human embryonic stem cells, induced pluripotent cells, or other sources, may alleviate dopa-responsive symptoms with a one-time surgical transplant procedure. We predict that this would alleviate “off time” for patients whose medications do not provide for smooth symptom control. Concurrently, another avenue under investigation involves the use of mesenchymal stem cells (MSCs), that may provide benefit via a fundamentally different mechanism of action. Clinical trials are now underway globally to rigorously test safety and tolerability of these innovative interventions, and to gain initial information on the behavior and clinical effects of these interventions.

Claire Henchcliffe, M.D., D.Phil. is the Chair and Stanley van den Noort Professor of Neurology, University of California, Irvine since 2020. Prior to this, she spent 17 years at Weill Cornell Medical College (WCMC)/New York Presbyterian Hospital, New York City, becoming Professor of Neurology and Neuroscience, and Vice Chair for Clinical Research in Neurology. Her clinical and research focus is on Parkinson’s disease and related neurodegenerative disorders, including working to develop new Parkinson’s disease therapeutics such as stem cell-based and gene therapy interventions.

Clearpoint Neuro: Understanding MRI-Guided Delivery System 

Presentation on understanding MRI-guided delivery system for cell-based therapies.

Paul Knoepfler, PhD

Bad Actor Stem Cell Clinics – How to Protect Yourself

About Paul Knoepfler, PhD: Professor, Department of Cell Biology and Human Anatomy, the Genome Center, and the Comprehensive Cancer Center at University of California, Davis School of Medicine. Author of THE NICHE, a stem cell blog calling itself the longest running blog of its type.

About Summit’s Educational Programs: 

It is important to Summit that you, your medical team, and your caregivers understand stem cells and stem cell-based therapies (cell therapies) when considering treatment options. We provide: 

Educational Webinars are designed to bridge the educational gap between fast-paced scientific discoveries and the public and especially, the medical community.

Featuring globally respected and renowned speakers providing information on current topics.

Reliable information and updates on stem cells and regenerative medical research – including clinical trial information as we receive it.

Thanks to the generosity of our SPONSORS, our webinars are FREE to everyone.

Our attendees are from all over the United States and from around the globe. They include members of the medical community, patients, caregivers, academia, research & pharmacology communities, students, and, ultimately, anyone interested in the great strides being made in the field of regenerative medicine and stem cells. 


To view past Webinars:  Click HERE_ Educational Programs 

Extra special thanks to our sponsors!

Special Thanks to our Sponsors

All 2023 Webinars are FREE thanks in part to our sponsors: 

All 2021 & 2022  Webinars are FREE to viewers thanks to the generosity of our sponsor: The Seim Family.